Higgs mass determination from direct reconstruction at a Linear e=e- Collider

We study the feasibility of a precise measurement of the mass of a 120 GeV MSM Higgs boson through direct reconstruction of ZH->qqH events that would be achieved in a future e+e- linear collider operating at a center-of-mass energy of 500 GeV. Much effort has been put in a ``realistic simulation'' by including irreducible and reducible backgrounds, realistic detector effects and reconstruction procedures and sophisticated analysis tools involving Neural Networks and kinematical fitting. As a result, the Higgs mass is determined with a statistical accuracy of 50 MeV and the Z-Higgs Yukawa coupling measured to 0.7%, assuming 500 fb^-1 of integrated luminosity.Comment: LaTex, 29 pages, 18 Postscript figure

Government Equity Participation Under the EEC Rules on State Aids: Recent Developments

This Article examines the main legal questions raised by the particulat form of State aid known as equity participation. While the focus is on the internal, or EEC, aspect of such aids, the Article also suggests a comparison to some of the most relevant external, or GATT, aspects of these questions

Protein Functional Families to characterise drug-target interactions.

The quest for “magic bullets” has been the driving force in drug discovery during the last two decades. However, the increasing rate of drug failure over this period has occurred concurrently with the assumption that a drug is a selective ligand for a single target. It now seems likely that polypharmacology is the rule rather than the exception [1]. Our previous research shows that protein domains are a good proxy for drug targets, and that drug polypharmacology emerges as a consequence of the multi-domain composition of proteins [2]. In this study, we investigate further the idea that the domain is the druggable entity within a protein target. We have identified a specific class of domains (CATH Functional Families) as the best currently available for identifying drug-target interactions. We show how this opens a new direction in target identification with potential application in drug repurposing.1. Hopkins, AL. (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol; 4: 682 2. Moya-García AA & Ranea JAG (2013) Insights into polypharmacology from drug-domain associations. Bioinformatics 29: 1934–1937)Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech. Universidad de Granad